AUPH · Aurinia Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $77.70M | - | $73.47M | $70.01M | $62.47M | - | $67.77M | $57.19M | $50.30M | - |
| Cost of Revenue | $6.50M | - | $8.18M | $7.12M | $8.57M | - | $6.04M | $8.91M | $7.75M | - |
| Gross Profit | $71.20M | - | $65.29M | $62.89M | $53.89M | - | $61.74M | $48.28M | $42.55M | - |
| R&D | $7.47M | - | $8.44M | $7.43M | $5.74M | - | $3.05M | $4.08M | $5.55M | - |
| SG&A | $22.03M | - | $26.18M | $26.02M | $20.34M | - | $42.37M | $44.93M | $47.70M | - |
| Total Operating Expenses | $36.28M | - | $43.72M | $49.92M | $40.62M | - | $56.02M | $58.70M | $63.56M | - |
| D&A | $4.82M | - | - | - | $4.85M | - | - | - | $4.85M | - |
| Operating Income | $41.42M | - | $29.75M | $20.08M | $21.85M | - | $11.75M | ($1.51M) | ($13.25M) | - |
| Interest Expense | $1.01M | - | $1.10M | $1.20M | $1.28M | - | $1.21M | $1.20M | $1.28M | - |
| Income Tax | $9.57M | - | $411.0K | $643.0K | $1.00M | - | $457.0K | $756.0K | $739.0K | - |
| Net Income | $34.35M | - | $31.55M | $21.51M | $23.34M | - | $14.35M | $722.0K | ($10.75M) | - |
| EPS - Basic | $0.26 | - | $0.24 | $0.16 | $0.17 | - | $0.10 | $0.01 | ($0.07) | - |
| EPS - Diluted | $0.25 | - | $0.23 | $0.16 | $0.16 | - | $0.10 | $0.01 | ($0.07) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $40.75M | $80.16M | $72.89M | $52.91M | $66.11M | $83.40M | $36.63M | $33.27M | $63.91M | $48.76M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $46.41M | $45.69M | $44.79M | $46.50M | $46.20M | $39.23M | $38.71M | $38.85M | $39.76M | $39.70M |
| Accounts Payable | $2.66M | $3.31M | $2.21M | $3.31M | $4.22M | $5.19M | $8.88M | $8.41M | $5.67M | $4.33M |
| Current Assets | $480.24M | $491.97M | $438.74M | $408.97M | $405.76M | $446.60M | $440.46M | $409.67M | $398.22M | $424.80M |
| Total Assets | $724.00M | $751.59M | $527.53M | $502.56M | $504.85M | $550.64M | $549.36M | $523.53M | $516.63M | $548.06M |
| Current Liabilities | $86.56M | $93.72M | $76.22M | $78.27M | $68.41M | $97.76M | $78.61M | $76.90M | $71.05M | $77.19M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $156.37M | $170.26M | $161.76M | $167.26M | $154.66M | $173.17M | $161.36M | $158.91M | $157.16M | $170.11M |
| Stockholders' Equity | $567.63M | $581.33M | $365.77M | $335.30M | $350.19M | $377.48M | $388.00M | $364.62M | $359.48M | $377.95M |
| Retained Earnings | ($615.01M) | ($649.37M) | ($860.16M) | ($891.71M) | ($913.23M) | ($936.57M) | ($938.00M) | ($952.35M) | ($953.07M) | ($942.32M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $32.56M | - | - | - | $1.30M | - | - | - | ($18.60M) | - |
| Investing Cash Flow | ($18.08M) | - | - | - | $31.03M | - | - | - | $49.23M | - |
| Financing Cash Flow | ($53.69M) | - | - | - | ($49.34M) | - | - | - | ($15.05M) | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 91.6% | - | 88.9% | 89.8% | 86.3% | - | 91.1% | 84.4% | 84.6% | - |
| Operating margin | 53.3% | - | 40.5% | 28.7% | 35.0% | - | 17.3% | -2.6% | -26.3% | - |
| EBITDA margin | 59.5% | - | - | - | 42.7% | - | - | - | -16.7% | - |
| Net margin | 44.2% | - | 42.9% | 30.7% | 37.4% | - | 21.2% | 1.3% | -21.4% | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | 9.6% | - | 11.5% | 10.6% | 9.2% | - | 4.5% | 7.1% | 11.0% | - |
| SG&A / Revenue | 28.3% | - | 35.6% | 37.2% | 32.6% | - | 62.5% | 78.6% | 94.8% | - |
| Effective tax rate | 21.8% | - | 1.3% | 2.9% | 4.1% | - | 3.1% | 51.2% | - | - |
| Return on assets | 4.7% | - | 6.0% | 4.3% | 4.6% | - | 2.6% | 0.1% | -2.1% | - |
| Return on equity | 6.1% | - | 8.6% | 6.4% | 6.7% | - | 3.7% | 0.2% | -3.0% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.55 | 5.25 | 5.76 | 5.23 | 5.93 | 4.57 | 5.60 | 5.33 | 5.60 | 5.50 |
| Quick ratio | 5.01 | 4.76 | 5.17 | 4.63 | 5.26 | 4.17 | 5.11 | 4.82 | 5.05 | 4.99 |
| Cash ratio | 0.47 | 0.86 | 0.96 | 0.68 | 0.97 | 0.85 | 0.47 | 0.43 | 0.90 | 0.63 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 40.9x | - | 27.1x | 16.8x | 17.0x | - | 9.7x | -1.3x | -10.3x | - |
| Equity multiplier | 1.28 | 1.29 | 1.44 | 1.50 | 1.44 | 1.46 | 1.42 | 1.44 | 1.44 | 1.45 |
| Liabilities / Assets | 0.22 | 0.23 | 0.31 | 0.33 | 0.31 | 0.31 | 0.29 | 0.30 | 0.30 | 0.31 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.14 | 0.14 | 0.12 | - | 0.12 | 0.11 | 0.10 | - |
| Inventory turnover | 0.14 | - | 0.18 | 0.15 | 0.19 | - | 0.16 | 0.23 | 0.19 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 2604d | - | 1999d | 2386d | 1967d | - | 2341d | 1592d | 1872d | - |
| Days payable outstanding | 149d | - | 99d | 170d | 180d | - | 537d | 345d | 267d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | 59.3x | - | 48.0x | 52.9x | 50.2x | - | 73.3x | 571.0x | - | - |
| P / B | 3.6x | - | 4.1x | 3.5x | 3.3x | - | 2.8x | 2.3x | 2.0x | - |
| P / S | 26.3x | - | 20.5x | 16.6x | 18.4x | - | 15.8x | 14.4x | 14.3x | - |
| EV / EBITDA | 43.2x | - | - | - | 40.7x | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 24.4% | - | 8.4% | 22.4% | 24.2% | - | 24.3% | 37.8% | 46.2% | - |
| Revenue CAGR (3y) | 31.2% | - | 9.6% | 35.4% | 42.4% | - | 66.6% | 105.2% | 280.4% | - |
| Revenue CAGR (5y) | 143.2% | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 32.1% | - | 5.8% | 30.3% | 26.7% | - | 29.3% | 20.9% | 25.2% | - |
| Operating income growth (YoY) | 89.6% | - | 153.2% | - | - | - | - | 90.6% | 55.2% | - |
| Net income growth (YoY) | 47.2% | - | 119.9% | 2879.6% | - | - | - | - | 59.0% | - |
| EPS growth (YoY) | 56.3% | - | 130.0% | 1500.0% | - | - | - | - | 61.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 62.1% | 54.0% | -5.7% | -8.0% | -2.6% | -0.1% | -1.0% | -7.1% | -7.9% | -6.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$294.75M totalProduct$271.35M · 92.1%
License Collaboration And Royalty Revenue$11.71M · 4.0%
Service$11.70M · 4.0%
Geographic
$283.06M totalUS$263.84M · 93.2%
JP$19.21M · 6.8%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aurinia Pharmaceuticals Inc. against the 5 most active filers in the same SIC group.